GET DAILY SIGNALSOrchestra BioMed Holdings (OBIO): What the $13 Analyst Target Means for Investors
Key Takeaways
- The central target of $13 is the arithmetic mean of seven verified, current analyst price targets, rounded from roughly $12.70.
- At a recent close of $5.68, Orchestra BioMed Holdings, Inc. (OBIO) would need to rise about 129% to reach $13, a very large move.
- Individual targets span a wide range from $10 to $20, reflecting genuine disagreement about the value of the company's clinical pipeline.
- The strongest supporting factor is the company's partnership model with Medtronic and Terumo and its late-stage cardiovascular programs, AVIM therapy and Virtue SAB.
- The biggest risks are clinical and regulatory execution, a pre-revenue business model, and persistent operating losses that may require further dilution.
- You can find more detail on Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- Explore Trending AI Robots to see AI-driven strategies actively tracking opportunities like this one.
Breaking Down the Analyst Consensus
Orchestra BioMed Holdings, Inc. (OBIO) is a Nasdaq-listed biomedical innovation company that develops medical device technologies through risk-sharing partnerships with large device makers. Seven verifiable, current analyst targets form the basis of this analysis. The targets, by firm, are approximately: H.C. Wainwright at $10, Piper Sandler at $10, BTIG at $10, B. Riley at $11, Barclays at $13, TD Cowen at $15, and Chardan Capital at $20. The arithmetic mean is about $12.70, and the rounded central target used here is $13. The range is notably wide, from $10 to $20.
The average analyst rating is a Strong Buy, and several firms have raised or reiterated bullish calls through 2026. Barclays lifted its target from $12 to $13, TD Cowen reiterated at $15, and Chardan Capital holds the high end at $20. Piper Sandler and B. Riley both moved their targets higher, while BTIG upgraded the name to Buy. The spread reflects uncertainty about how the market should value a pre-revenue, clinical-stage device company whose worth depends heavily on pivotal trial outcomes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
OBIO closed at $5.68 on November 6, 2026, with a market capitalization of roughly $340 million to $350 million. Reaching $13 would require an upside of approximately 129%, which qualifies as a very large move. The stock trades below its 52-week high of about $6.50 and well above its 52-week low near $3.46, so it has already demonstrated meaningful volatility.
The path to the target would likely be driven by data catalysts rather than ordinary earnings growth, because the company reports minimal revenue and is unprofitable. OBIO is advancing the BACKBEAT pivotal study for AVIM therapy in hypertension patients with pacemakers, in collaboration with Medtronic, and has received FDA approval of an amended investigational device exemption (IDE) for a U.S. pivotal study of Virtue SAB in coronary in-stent restenosis, partnered with Terumo. Positive clinical or regulatory milestones could compress the valuation gap, while setbacks could widen it.
Factors That Could Support a Move Toward the Target
- Partnerships with Medtronic and Terumo provide development funding, commercial reach, and external validation of the pipeline.
- Completion of enrollment in the BACKBEAT study and initiation of the Virtue SAB U.S. pivotal study represent near-term, identifiable catalysts.
- A $20 million convertible loan from Medtronic (announced for April 2026) strengthens the balance sheet and signals continued strategic commitment.
- Analyst sentiment is broadly positive, with multiple firms reiterating or raising targets during 2026.
Risks That Could Prevent the Target From Being Reached
- The company remains pre-revenue in practical terms, reporting minimal sales and a quarterly net loss in the tens of millions of dollars.
- Clinical trials carry inherent risk; disappointing BACKBEAT or Virtue SAB data could materially reset valuations.
- Ongoing cash consumption may require additional equity raises, creating dilution risk for existing shareholders.
- A wide analyst range of $10 to $20 shows limited consensus on intrinsic value, and the stock has already pulled back from its 52-week high.
Technical Levels and Market Structure
The stock's 52-week high near $6.50 and low near $3.46 frame the recent trading range. A sustained move above the $6.50 area would represent a breakout from that range, while the $4.50 to $4.80 zone has served as a support area in recent technical data. These are structural reference points rather than precise forecasts, but they help investors gauge where buyers and sellers have previously stepped in. From what I see, monitoring these levels alongside clinical updates remains useful.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though firms may apply shorter or longer views. The key items to monitor are the pace of BACKBEAT enrollment and completion, initiation and enrollment of the Virtue SAB U.S. pivotal study, any additional partnership or financing announcements, quarterly cash balances, and analyst target revisions. Regulatory decisions and broader market appetite for clinical-stage biotech and device names also matter.
Final Assessment
The $13 central target is a rounded average of seven current analyst price targets ranging from $10 to $20, not a guarantee or an official published consensus. At $5.68, reaching it would require a very large move of about 129%. Support comes from high-profile partnerships, late-stage pipeline catalysts, and broadly bullish analyst sentiment, while the principal obstacles are clinical risk, a pre-revenue model, and potential dilution. The wide spread between the lowest and highest targets underscores genuine disagreement about valuation, so investors should focus on upcoming clinical milestones, cash runway, and analyst revisions rather than any single figure.
Using Tickeron’s AI Daily Buy/Sell Signals for Monitoring
I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful for keeping tabs on names like OBIO. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. It serves as a practical complement to reviewing clinical updates and analyst reports, especially when tracking a stock with event-driven catalysts ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OBIO saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for OBIO moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In 45 of the 56 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for OBIO turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
OBIO moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on OBIO as a result. In 64 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The 10-day moving average for OBIO crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where OBIO advanced for three days, in 164 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
OBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 130 of 181 cases where OBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.668) is normal, around the industry mean (3.498). P/E Ratio (-6.762) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.198) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement